Bexagliflozin Tablet
Product Images NDC 82381-2000

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bexagliflozin (NDC 82381-2000). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Theracosbio, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bexagliflozin-label-30s (Bexagliflozin 20 mg 30 Tablets)

This is a description of Bexagliflozin Tablets 20 mg. The tablets contain Bexagliflozin 20 mg and should not be accepted if the bottle seal is broken or missing. They should be stored at a temperature between 20°C to 25°C (68°F to 77°F). It is advised not to crush or chew the tablets. Each bottle contains 30 tablets and should be dispensed with the enclosed Medication Guide to each patient. Distributed by TheracosBio, LLC based in Marlborough, MA, the tablets are for prescription use only. The NDC number is 82381-2000-8.*

FDA Label Image

Bexagliflozin-label-90s (Bexagliflozin 20 mg 90 Tablets)

This is a description for Bexagliflozin tablets with 20 mg dosage. Each tablet contains bexagliflozin. The tablets should not be accepted if the bottle seal is broken or missing. They should be kept out of reach of children and stored at 20 to 25 degrees Celsius. The tablets should not be crushed or chewed. Dosage information can be found in the prescribing medication guide. The product is distributed by a specific pharmaceutical company.*

FDA Label Image

Bexagliflozin-figure-1 (Bexagliflozin Figure 1)

FDA Label Image

Bexagliflozin-figure-2 (Bexagliflozin Figure 2)

The text provides information on the pharmacokinetic parameters (AUC and Cmax) of Metformin, Glimepiride, Stagliptin, and Digoxin at certain doses. It also mentions the Geometric Mean Ratio with 90% confidence intervals for comparison purposes. This data may be part of a clinical study or drug interaction analysis.*

FDA Label Image

Bexagliflozin-figure-3 (Bexagliflozin Figure 3)

This information appears to be a comparison between the drug "BRENZAVVY" and a placebo. The data seems to show the measured values of Bex and Pbo over a span of 24 weeks. The values for Bex appear to decrease from 138 to 124, while the values for Pbo decrease from 69 to 64 and then back to 69. The trend of the two substances over the duration of the study could indicate the efficacy of the drug compared to the placebo.*

FDA Label Image

Bexagliflozin-structure (Bexagliflozin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.